ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SLGL vs KROS // EV/EBITDA & P/E VALUATION

Sol-Gel Technologies Ltd. (NASDAQ) VS. Keros Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: SLGL 2 — KROS 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SLGL VS. KROS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SLGL KROS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 85.00% -120.00 KROS /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield 0.12% — — TIE /fcf-yield <GO>
Operating Margin -38.90% 27.70% -66.60 KROS /operating-margins <GO>
Net Profit Margin -31.60% 35.70% -67.30 KROS /net-margins <GO>
Revenue Growth (YoY) 68.00% 180.00% -112.00 KROS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 8.54 4.31 +4.23 SLGL /balance-sheet <GO>
Piotroski F-Score Quality 6/9 8/9 -2.00 KROS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.5 40.6 +0.95 SLGL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $224.8M $225.2M -$444.1K KROS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SLGL REV KROS REV SLGL GROSS % KROS GROSS % SLGL FCF KROS FCF
FY 2025 $19.4M $244.1M — — $275.0K $106.0M
FY 2024 $11.5M $3.5M — — -$13.9M -$162.8M
FY 2023 $1.6M $151.0K — — -$17.7M -$124.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SLGL // BETA —
KROS // BETA —